Email Updates

You are here

HIV vax in advanced trial posts promising 2-Year results

Include in
Media Coverage

The experimental HIV vaccine currently under investigation in an advanced trial has shown promising 96-week results from an earlier human study. The so-called mosaic vaccine offered a broad array of immune responses to the virus at this point, and such responses persisted up to a year after the last vaccination shot.

July 25, 2018